ALLMedicine™ Pelvic Lymph Node Dissection Center

Mar 10th, 2023 - Accurate lymph node staging is important for the diagnosis and treatment of patients with bladder cancer. We aimed to develop a lymph node metastases diagnostic model (LNMDM) on whole slide images and to assess the clinical effect of an artificial...

Mar 9th, 2023 - This is a study of perioperative pembrolizumab or enfortumab vedotin in combination with pembrolizumab in participants who are cisplatin-ineligible or decline cisplatin with muscle-invasive bladder cancer (MIBC). The primary hypothesis is that per...

Mar 9th, 2023 - Radical prostatectomy (RP) is the surgical standard treatment for men with localized prostate cancer (PCa) and a life expectancy of > 10 years. RP is a treatment option for localized PCa that shows benefit in prostate cancer-specific survival (PCS...

Mar 7th, 2023 - The incidence of cervical cancer in developed countries declined considerably in the last few decades. This has been possible for efficient screening programs to which HPV vaccines have been added over the past 15 years. Despite this global reduct...

Mar 7th, 2023 - PRIMARY OBJECTIVES: I. To determine if axitinib modulates pre-metastatic niche density in patients with high-risk prostate cancer. SECONDARY OBJECTIVES: I. To determine if pre-metastatic niche density in regional lymph nodes (LNs) is associated wi...

Apr 27th, 2016 - The third version of the Japan Society of Gynecologic Oncology guidelines for the treatment of uterine body neoplasms was published in 2013. The guidelines comprise nine chapters and nine algorithms. Each chapter includes a clinical question, reco...

Jan 18th, 2015 - The technique of robot-assisted radical cystectomy (RARC) has evolved significantly since its inception >10 yr ago. Several high-volume centers have reported standardized techniques with refinements and subsequent outcomes. To review all existing ...

Mar 9th, 2023 - This is a study of perioperative pembrolizumab or enfortumab vedotin in combination with pembrolizumab in participants who are cisplatin-ineligible or decline cisplatin with muscle-invasive bladder cancer (MIBC). The primary hypothesis is that per...

Mar 9th, 2023 - Radical prostatectomy (RP) is the surgical standard treatment for men with localized prostate cancer (PCa) and a life expectancy of > 10 years. RP is a treatment option for localized PCa that shows benefit in prostate cancer-specific survival (PCS...

Mar 7th, 2023 - PRIMARY OBJECTIVES: I. To determine if axitinib modulates pre-metastatic niche density in patients with high-risk prostate cancer. SECONDARY OBJECTIVES: I. To determine if pre-metastatic niche density in regional lymph nodes (LNs) is associated wi...

Mar 7th, 2023 - The incidence of cervical cancer in developed countries declined considerably in the last few decades. This has been possible for efficient screening programs to which HPV vaccines have been added over the past 15 years. Despite this global reduct...

Mar 3rd, 2023 - The purpose of this study is to assess the antitumor efficacy and safety of perioperative enfortumab vedotin (EV) plus pembrolizumab and radical cystectomy (RC) + pelvic lymph node dissection (PLND) compared with the current standard of care (neoa...

Aug 12th, 2022 - Among men in the United States, incidence-based mortality (IBM) is growing for penile cancer even though incidence remained consistent from 2000 to 2018. Existing treatments are of limited efficacy, and there has been a lack research that might id...

Jul 26th, 2022 - Transcript: Evan Y. Yu, MD: Let's move on to module 2 which is focused on advances in non-metastatic or M0 castration resistant prostate cancer so let's discuss the case. This is a 64 year old gentleman who presents with nocturia has a past medic...

Mar 24th, 2022 - David O’Malley, MD: Let’s go to our third case. This is a 64-year-old post-menopausal patient who presented with a big uterus. She’s tender, she has a bunch of blood, and she’s feeling unwell. With an 18-cm uterus, we did an exploratory laparotomy...

Mar 23rd, 2022 - The addition of atezolizumab (Tecentriq) to neoadjuvant gemcitabine and cisplatin (GC) generated a high rate of non–muscle-invasive downstaging following radical cystectomy, which correlated with improved relapse-free survival (RFS) and overall su...

Mar 18th, 2022 - Enfortumab vedotin (Padcev) produced promising antitumor activity when used as neoadjuvant treatment in patients with muscle invasive bladder cancer (MIBC) who were not eligible for cisplatin, according to preliminary findings from cohort H of the...